文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

HLA信息可预测单倍体相合干细胞移植联合移植后环磷酰胺后的风险

HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide.
PubMed 文献 · Blood · 2022-01-01

该研究基于国际血液与骨髓移植研究中心报告的1434例急性白血病或骨髓增生异常综合征患者,分析单倍体相合供者移植联合移植后环磷酰胺后供者HLA错配对GVHD、疾病复发和生存的影响。结果显示,结局与单个位点的HLA(错)配相关而非HLA错配总数,HLA-DRB1错配与较低复发风险相关,HLA-B leader匹配和HLA-DPB1 TCE非允许错配各与总生存改善相关,HLA-C匹配降低慢性GVHD风险。作者据此开发了基于HLA等因素计算无病生存的网页工具,并认为HLA因素有助于优化单倍体相合供者选择。

要点

  • 结局与单个位点HLA(错)配相关,而非HLA错配总数。
  • HLA-DRB1错配与较低疾病复发风险相关;HLA-DRB1错配且HLA-DQB1匹配与无病生存改善相关。
  • HLA-B leader匹配和HLA-DPB1 TCE非允许错配各与总生存改善相关;HLA-C匹配降低慢性GVHD风险。

核心结论

  • HLA因素影响单倍体相合移植联合PTCy的成功,HLA-DRB1和-DPB1错配以及HLA-C、-B leader和-DQB1匹配为有利因素。
  • 考虑HLA因素可能有助于优化单倍体相合相关供者的选择。

研究设计与样本

  • 研究纳入1434例急性白血病或骨髓增生异常综合征患者,数据报告至国际血液与骨髓移植研究中心。
  • 采用多变量回归方法研究移植物抗宿主方向HLA-A、-B、-C、-DRB1和-DQB1等位基因错配、HLA-B leader及HLA-DPB1 T细胞表位(TCE)的影响。

主要发现

  • HLA-DRB1错配与较低疾病复发风险相关。
  • HLA-DRB1错配且HLA-DQB1匹配与无病生存改善相关。
  • HLA-B leader匹配和HLA-DPB1 TCE非允许错配各与总生存改善相关。
  • HLA-C匹配降低慢性GVHD风险,HLA-C表达水平与移植相关死亡率相关。
  • HLA-B leader及HLA-DRB1、-DQB1、-DPB1的匹配状态可预测无病生存,患者和供者巨细胞病毒血清状态、患者年龄及合并症指数亦可预测。

关键数值与推荐

  • HLA-DRB1错配与较低疾病复发风险相关。
  • HLA-DRB1错配且HLA-DQB1匹配与无病生存改善相关。
  • HLA-B leader匹配与总生存改善相关;HLA-DPB1 TCE非允许错配与总生存改善相关。
  • HLA-C匹配降低慢性GVHD风险;HLA-C表达水平与移植相关死亡率相关。
  • 基于HLA-B leader及HLA-DRB1、-DQB1、-DPB1匹配状态、患者和供者巨细胞病毒血清状态、患者年龄及合并症指数计算无病生存的网页工具已开发。

临床怎么用

  • 作者认为,考虑HLA因素可能有助于优化单倍体相合相关供者的选择。
  • 已开发网页工具,可基于HLA-B leader及HLA-DRB1、-DQB1、-DPB1匹配状态、患者和供者巨细胞病毒血清状态、患者年龄及合并症指数计算无病生存,以辅助选择最佳单倍体相合相关供者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly used to treat hematologic cancers; however, characteristics of the optimal haploidentical donor have not been established. We studied the role of donor HLA mismatching in graft-versus-host disease (GVHD), disease recurrence, and survival after haploidentical donor transplantation with posttransplantation cyclophosphamide (PTCy) for 1434 acute leukemia or myelodysplastic syndrome patients reported to the Center for International Blood and Marrow Transplant Research. The impact of mismatching in the graft-versus-host vector for HLA-A, -B, -C, -DRB1, and -DQB1 alleles, the HLA-B leader, and HLA-DPB1 T-cell epitope (TCE) were studied using multivariable regression methods. Outcome was associated with HLA (mis)matches at individual loci rather than the total number of HLA mismatches. HLA-DRB1 mismatches were associated with lower risk of disease recurrence. HLA-DRB1 mismatching with HLA-DQB1 matching correlated with improved disease-free survival. HLA-B leader matching and HLA-DPB1 TCE-nonpermissive mismatching were each associated with improved overall survival. HLA-C matching lowered chronic GVHD risk, and the level of HLA-C expression correlated with transplant-related mortality. Matching status at the HLA-B leader and HLA-DRB1, -DQB1, and -DPB1 predicted disease-free survival, as did patient and donor cytomegalovirus serostatus, patient age, and comorbidity index. A web-based tool was developed to facilitate selection of the best haploidentical-related donor by calculating disease-free survival based on these characteristics. In conclusion, HLA factors influence the success of haploidentical transplantation with PTCy. HLA-DRB1 and -DPB1 mismatching and HLA-C, -B leader, and -DQB1 matching are favorable. Consideration of HLA factors may help to optimize the selection of haploidentical related donors.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Fuchs EJ, McCurdy SR, Solomon SR, et al. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood. 2022. PMID: 34724567. doi:10.1182/blood.2021013443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。